Best Practice & Research in Clinical Rheumatology最新文献

Novel therapies for axial spondyloarthritis and future directions. 轴性脊柱炎的新疗法及未来发展方向。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-10-09 DOI: 10.1016/j.berh.2025.102105

Marta Dzhus, Walter P Maksymowych

引用次数: 0

Novel therapies in treatments of SLE. SLE治疗的新疗法。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-10-07 DOI: 10.1016/j.berh.2025.102101

Yoshiya Tanaka

引用次数: 0

Contemporary approaches to the management of rheumatoid arthritis: precision and progress. 类风湿关节炎的当代治疗方法：精确与进步。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-10-01 DOI: 10.1016/j.berh.2025.102106

Tania Gudu, Mert Oztas, Elena Nikiphorou

{"title":"Contemporary approaches to the management of rheumatoid arthritis: precision and progress.","authors":"Tania Gudu, Mert Oztas, Elena Nikiphorou","doi":"10.1016/j.berh.2025.102106","DOIUrl":"https://doi.org/10.1016/j.berh.2025.102106","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting synovial joints and extra-articular organs. While conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) like methotrexate remain the cornerstone of therapy, nearly half of patients demonstrate inadequate response to monotherapy. This review provides a comprehensive overview of the evolving therapeutic landscape in RA, covering standard therapies, novel treatments, and precision medicine approaches. The treatment landscape has dramatically expanded with biologic DMARDs targeting TNF-α, IL-6, B and T cells, and more recently, targeted synthetic DMARDs such as the Janus kinase inhibitors (JAKi). Emerging therapies are discussed, including innovative cell-based approaches, that will likely continue to revolutionize the treatment o. Furthermore, treatment failure, in the context of difficult-to-treat disease and factors associated with this, are addressed. We explore biomarker-driven treatment selection utilizing autoantibodies, imaging, and synovial tissue analysis and address key challenges around drug safety concerns, managing comorbidities and difficult-to-treat RA. Finally, this article concludes with reflections on future directions and the role of machine learning, multi-omics technologies, while maintaining the focus on patient-centered approaches to care.</p>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":" ","pages":"102106"},"PeriodicalIF":4.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What's new in osteoarthritis? 骨关节炎有什么新进展？

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-10-01 DOI: 10.1016/j.berh.2025.102102

Graeme Jones

引用次数: 0

Novel therapies in SSc. SSc的新疗法。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-09-30 DOI: 10.1016/j.berh.2025.102104

Janet Pope

引用次数: 0

Novel Therapy. 新颖的治疗。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-09-25 DOI: 10.1016/j.berh.2025.102103

Mitsumasa Kishimoto, Peter Nash

引用次数: 0

Novel therapies in osteoporosis - Clinical update - 2025. 骨质疏松症的新疗法-临床更新- 2025。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-09-24 DOI: 10.1016/j.berh.2025.102100

Charles Inderjeeth, Diren Che Inderjeeth

{"title":"Novel therapies in osteoporosis - Clinical update - 2025.","authors":"Charles Inderjeeth, Diren Che Inderjeeth","doi":"10.1016/j.berh.2025.102100","DOIUrl":"https://doi.org/10.1016/j.berh.2025.102100","url":null,"abstract":"<p><p>Rheumatological patients are at high risk of osteoporosis and fracture due to disease, treatments, comorbidity and physical and functional considerations. Treating osteoporosis optimally is paramount. Osteoporosis management is evolving rapidly beyond traditional therapies. This 2025 review examines available traditional therapies and novel pharmacological approaches developed. Key questions addressed include the mechanisms, efficacy, and safety of agents like the sclerostin inhibitor romosozumab, Parathyroid hormone targeted agents, cytokine inhibitors and the status of therapies targeting cathepsin K. We evaluate the growing importance of combined and sequential treatment strategies, particularly initiating potent anabolic or dual-action therapies followed by antiresorptives for high-risk patients. Furthermore, the review explores emerging therapeutic targets such as modulators of the Wnt pathway, inflammation, and bone cell metabolism, alongside advancements in drug delivery, gene therapy, and non-pharmacological interventions. Clinical implications for patient selection, monitoring, and navigating the expanding treatment landscape are discussed, highlighting future directions towards personalized osteoporosis care.</p>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":" ","pages":"102100"},"PeriodicalIF":4.8,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145151689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pipeline treatments on psoriatic disease. 银屑病的管道治疗。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-09-22 DOI: 10.1016/j.berh.2025.102090

André L Ribeiro, Leandro L Leite, Raphael Micheroli, Daniela B Tovar-Batisdas, Maria-Angeliki Gkini, Fabian Proft

{"title":"Pipeline treatments on psoriatic disease.","authors":"André L Ribeiro, Leandro L Leite, Raphael Micheroli, Daniela B Tovar-Batisdas, Maria-Angeliki Gkini, Fabian Proft","doi":"10.1016/j.berh.2025.102090","DOIUrl":"https://doi.org/10.1016/j.berh.2025.102090","url":null,"abstract":"<p><p>Psoriatic disease is a heterogeneous and multifaceted disease affecting musculoskeletal, dermatologic, and systemic domains, with low sustained remission rates despite advances in therapy. Current treatments, primarily targeting TNF, IL-17, IL-23, PDE4 inhibitors and JAK-STAT pathways, remain insufficient for many patients, highlighting the need for novel therapeutic approaches. This review explores pipeline treatments in psoriatic disease, including new JAK-STAT inhibitors (TYK2, JAK1), next-generation IL-17 inhibitors, IL-23-targeted therapies, and novel immune-modulating agents. The emerging role of combination therapy is also discussed, with dual biologic and small-molecule approaches showing potential in refractory disease. Additionally, microbiome-targeted therapies and metabolic interventions, including probiotics and GLP-1 receptor agonists, are being investigated as adjunctive strategies to improve disease control. While these innovations offer exciting opportunities for personalized medicine, challenges remain regarding long-term safety, optimal treatment sequencing, and combination strategies. Further randomized controlled trials and real-world data are necessary to define the most effective and sustainable treatment approaches for psoriatic disease.</p>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":" ","pages":"102090"},"PeriodicalIF":4.8,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145132501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging in sarcoid disease 结节病的影像学。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-09-01 DOI: 10.1016/j.berh.2025.102054

Sherief Ghozy , Jonathan W. Revels , Aakanksha Sriwastwa , Lily L. Wang , Jennifer S. Weaver , Sherry S. Wang

{"title":"Imaging in sarcoid disease","authors":"Sherief Ghozy , Jonathan W. Revels , Aakanksha Sriwastwa , Lily L. Wang , Jennifer S. Weaver , Sherry S. Wang","doi":"10.1016/j.berh.2025.102054","DOIUrl":"10.1016/j.berh.2025.102054","url":null,"abstract":"<div><div>Sarcoidosis is a complex multisystem inflammatory disease characterized by noncaseating granulomas and variable clinical manifestations, most commonly affecting the lungs, skin, heart, and nervous system. Imaging is central in its diagnosis, staging, and management, providing essential insights into organ involvement and disease activity. Pulmonary manifestations remain the hallmark, with modalities such as high-resolution chest computed tomography (CT) and chest radiography offering critical diagnostic clues. Imaging techniques, including Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and cardiac magnetic resonance imaging, are invaluable for identifying cardiac and systemic involvement, including cutaneous and musculoskeletal, while abdominal MRI and ultrasound help delineate hepatic and splenic manifestations. Neurosarcoidosis requires MRI for precise evaluation, supplemented by FDG-PET to guide biopsy and monitor treatment response. This chapter synthesizes the imaging features of sarcoidosis across organ systems, emphasizing practical approaches to diagnosis and management while identifying key areas for future research.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"39 3","pages":"Article 102054"},"PeriodicalIF":4.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging of crystal-induced arthropathies in 2025 2025年晶体诱发关节病的影像学研究。

IF 4.8 2区医学

Best Practice & Research in Clinical Rheumatology Pub Date : 2025-09-01 DOI: 10.1016/j.berh.2025.102063

Silvia Sirotti , Tristan Pascart , Ralf Thiele , Georgios Filippou

{"title":"Imaging of crystal-induced arthropathies in 2025","authors":"Silvia Sirotti , Tristan Pascart , Ralf Thiele , Georgios Filippou","doi":"10.1016/j.berh.2025.102063","DOIUrl":"10.1016/j.berh.2025.102063","url":null,"abstract":"<div><div>In recent years, imaging has become an essential tool in the assessment of crystal-induced arthropathies (CIAs), including gout, calcium pyrophosphate deposition disease, and basic calcium phosphate crystal deposition. Advances in imaging have improved diagnosis and disease monitoring, leading to its integration into classification criteria and clinical guidelines.</div><div>Ultrasound (US), conventional radiography (CR), and dual-energy computed tomography (DECT) each offer unique advantages. US is a widely accessible, cost-effective, and dynamic tool, while DECT provides crystal-specific images, aiding particularly in gout diagnosis. CR, though less sensitive to early crystal deposition, remains valuable for evaluating structural damage and chronic changes.</div><div>Despite these advances, challenges remain. The specificity and sensitivity of imaging findings need further validation, and the clinical relevance of certain imaging features is debated. This review summarizes recent developments, highlights key strengths, and discusses unresolved issues, emphasizing areas where future research is needed to optimize imaging use in CIAs.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"39 3","pages":"Article 102063"},"PeriodicalIF":4.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0